Literature DB >> 8728631

Spinal fusion in Duchenne's muscular dystrophy.

P D Brook1, J D Kennedy, L M Stern, A D Sutherland, B K Foster.   

Abstract

The Women's and Children's Hospital experience with Luque spinal fusion in Duchenne's muscular dystrophy was reviewed from its commencement in 1983 to the present with a view to assessing the clinical and radiologic outcome and safety of the procedure. Seventeen boys have undergone spinal fusion. L-rod instrumentation was used in 10, six of whom had significant problems with sitting imbalance or progression of the scoliosis or both. In seven cases, distal instrumentation was taken to the pelvis with a Galveston construct and rigid crosslinking. Apart from some progression and sitting imbalance in the L-rod group, there were few complications. In the Galveston group, pelvic obliquity was corrected by a mean of 63%, and there was better maintenance of correction. There were no pseudoarthroses or instrument failures in the Galveston group. Of the total group, four patients had forced vital capacity (FVC) values < 25% predicted, and two required ventilation postoperative (< 48 h). There were no other respiratory complications. The effect of surgery on respiratory function remains uncertain. Spinal fusion with the Luque rod construct and pelvic fixation is a safe procedure. It provided a mean correction of 60% and control of pelvic obliquity without significant postoperative deterioration. In our experience, surgery can be safely performed with FVC value down to 20% predicted. On the basis of these data, one current practice is to instrument to the pelvis with a Galveston construct and Texas Scottish Rite Hospital cross-linking.

Entities:  

Mesh:

Year:  1996        PMID: 8728631     DOI: 10.1097/00004694-199605000-00006

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  8 in total

1.  Management of the collapsing spine for patients with Duchenne muscular dystrophy.

Authors:  J J Rice; B L Jeffers; A T Devitt; F McManus
Journal:  Ir J Med Sci       Date:  1998 Oct-Dec       Impact factor: 1.568

2.  Pelvic fixation for neuromuscular scoliosis deformity correction.

Authors:  Romain Dayer; Jean Albert Ouellet; Neil Saran
Journal:  Curr Rev Musculoskelet Med       Date:  2012-06

3.  Evaluation of pelvic fixation in neuromuscular scoliosis: a retrospective study in 55 patients.

Authors:  Hitesh N Modi; Seung Woo Suh; Hae-Ryong Song; Jae Hyuk Yang; Nirmal Jajodia
Journal:  Int Orthop       Date:  2008-12-04       Impact factor: 3.075

4.  Treatment and complications in flaccid neuromuscular scoliosis (Duchenne muscular dystrophy and spinal muscular atrophy) with posterior-only pedicle screw instrumentation.

Authors:  Hitesh N Modi; Seung-Woo Suh; Jae-Young Hong; Jae-Woo Cho; Jong-Hoon Park; Jae-Hyuk Yang
Journal:  Eur Spine J       Date:  2009-11-03       Impact factor: 3.134

5.  The effect of posterior spinal fusion on respiratory function in Duchenne muscular dystrophy.

Authors:  W M Alexander; M Smith; B J C Freeman; L M Sutherland; J D Kennedy; P J Cundy
Journal:  Eur Spine J       Date:  2012-11-20       Impact factor: 3.134

6.  Rh-BMP-2 for L5-S1 arthrodesis in long fusions to the pelvis for neuromuscular spinal deformity in the pediatric age group: analysis of 11 patients.

Authors:  Loyola V Gressot; Akash J Patel; Steven W Hwang; Daniel H Fulkerson; Andrew Jea
Journal:  Childs Nerv Syst       Date:  2013-07-12       Impact factor: 1.475

Review 7.  Surgery for scoliosis in Duchenne muscular dystrophy.

Authors:  Daniel K L Cheuk; Virginia Wong; Elizabeth Wraige; Peter Baxter; Ashley Cole
Journal:  Cochrane Database Syst Rev       Date:  2015-10-01

8.  Correlation between the degree of correction of neuromuscular scoliosis and patient quality of life.

Authors:  David Gonçalves Nordon; Ariel Falbel Lugão; Lucas Castrillon Carmo Machado; Raphael Martus Marcon; Alexandre Fogaça Cristante; Tarcísio Eloy Pessoa de Barros; Olavo Biraghi Letaif
Journal:  Clinics (Sao Paulo)       Date:  2017-02-01       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.